Nuvalent to present pivotal ALKOVE-1 neladalkib data in ALK+ NSCLC at ASCO 2026

Nuvalent, Inc. Class A

Nuvalent, Inc. Class A

NUVL

0.00
  • Nuvalent scheduled pivotal results from ALKOVE-1 trial of neladalkib in TKI pre-treated advanced ALK-positive NSCLC for oral presentation at ASCO 2026 on May 29.
  • Data presentation will focus on overall efficacy and safety outcomes, targeting a patient group with prior kinase-inhibitor exposure.
  • Nuvalent also slated preliminary ARROS-1 results for zidesamtinib in advanced ROS1-positive solid tumors outside NSCLC for poster presentation at ASCO 2026 on May 30.
  • Company positioned both readouts as near-term clinical catalysts for its ALK and ROS1 selective inhibitor portfolio.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvalent Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE39253) on April 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.